We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

109 hedge funds and large institutions have $1.06B invested in Epizyme, Inc in 2018 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 38 increasing their positions, 30 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 14

42% more capital invested

Capital invested by funds: $749M → $1.06B (+$316M)

27% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 30

24% more call options, than puts

Call options by funds: $1.17M | Put options by funds: $947K

8% more funds holding

Funds holding: 101109 (+8)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

Holders
109
Holders Change
+8
Holders Change %
+7.92%
% of All Funds
2.5%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
23
Increased
38
Reduced
30
Closed
14
Calls
$1.17M
Puts
$947K
Net Calls
+$227K
Net Calls Change
-$881K
Name Holding Trade Value Shares
Change
Change in
Stake
OIM
26
Oracle Investment Management
Connecticut
$7.04M +$565K +33,433 +9%
Charles Schwab
27
Charles Schwab
California
$4.69M +$308K +18,255 +7%
Macquarie Group
28
Macquarie Group
Australia
$4.3M +$2.7M +159,636 +194%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$3.9M +$114K +6,769 +3%
JP Morgan Chase
30
JP Morgan Chase
New York
$3.47M +$3.12M +184,843 +1,749%
RPAM
31
Rhenman & Partners Asset Management
Sweden
$3.22M -$613K -36,300 -17%
Morgan Stanley
32
Morgan Stanley
New York
$3.08M +$1.07M +63,379 +57%
PP
33
PDT Partners
New York
$2.79M +$5.79K +343 +0.2%
UONDDL
34
University of Notre Dame du Lac
Indiana
$2.46M -$1.12M -66,169 -32%
California Public Employees Retirement System
35
California Public Employees Retirement System
California
$2.4M
Deutsche Bank
36
Deutsche Bank
Germany
$2.19M -$2.48M -146,991 -54%
Goldman Sachs
37
Goldman Sachs
New York
$2.17M -$171K -10,129 -8%
UBS Group
38
UBS Group
Switzerland
$2.04M +$1.73M +102,620 +847%
TCIM
39
TIAA CREF Investment Management
New York
$1.97M -$32.1K -1,901 -2%
AA
40
ALPS Advisors
Colorado
$1.65M +$273K +16,151 +21%
TA
41
Teachers Advisors
New York
$1.56M
Swiss National Bank
42
Swiss National Bank
Switzerland
$1.49M
QI
43
QS Investors
New York
$1.46M -$89.6K -5,306 -6%
CS
44
Credit Suisse
Switzerland
$1.44M +$115K +6,826 +9%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$1.32M -$46.5K -2,755 -4%
SCM
46
Sio Capital Management
New York
$1.29M +$1.23M +72,826 New
OM
47
Opaleye Management
Massachusetts
$1.24M +$1.18M +70,000 New
Marshall Wace
48
Marshall Wace
United Kingdom
$1.15M +$1.09M +64,651 New
Hudson Bay Capital Management
49
Hudson Bay Capital Management
Connecticut
$1.06M -$1.1M -65,000 -52%
VEA
50
Virtus ETF Advisers
New York
$1.05M +$537K +31,789 +115%

EPZM Hedge Fund Activity: Q1 2018 in Review

109 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q1 2018, worth a combined $1.06B — up 42% from $749M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new EPZM positions and 14 closed out — a net gain of 9 holders — while 38 added to existing stakes and 30 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $10.6M. The largest seller was Norges Bank, cutting an estimated $6.75M.

  • 109 institutional investors held Epizyme, Inc (EPZM) as of Q1 2018, up from 101 in Q4 2017.
  • Funds reported $1.06B of Epizyme, Inc stock for Q1 2018, up 42% quarter-over-quarter.
  • 23 funds opened new Epizyme, Inc positions in Q1 2018 and 14 closed out, a net change of +9 holders.
  • The largest Epizyme, Inc buyer in Q1 2018 was Point72 Asset Management, an estimated $10.6M added.
  • The largest Epizyme, Inc seller in Q1 2018 was Norges Bank, an estimated $6.75M sold.

Based on aggregated 13F filings for Q1 2018.